Novartis India Limited

Equities

NOVARTIND

INE234A01025

Pharmaceuticals

Market Closed - Bombay S.E. 12:03:59 2024-04-19 am EDT 5-day change 1st Jan Change
1,005 INR -2.46% Intraday chart for Novartis India Limited -3.92% +29.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novartis India Limited Announces Resignation of Nikhil Malpani as Company Secretary and Compliance Officer, Effective from April 30, 2024 CI
Novartis Eyes Sale of Listed Unit in India CI
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB... Our Logo
Swiss Market Index Closes in the Green on Healthcare Stocks Boost MT
Novartis Launches Strategic Review of Listed Indian Business MT
Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India CI
Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm CI
Dr Reddy'S In Race To Acquire Novartis AG's Stake In Novartis India - CNBC TV-18 RE
Novartis India Limited Announces Completion of Tenure of Jai Hiremath as Independent Director, Effective March 31, 2024 CI
Novartis AG Announces A Strategic Review of India Unit CI
Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Managing Director, Effective April 02, 2024 CI
Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Vice-Chairman, Effective April 02, 2024 CI
Novartis India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Novartis India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Novartis India Limited Announces Change in Registered Office Address CI
Novartis India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Novartis India Limited Proposes One-Time Special Dividend CI
Pfizer's India unit posts 3% rise in Q4 profit RE
Novartis India Limited Recommends One-Time Special Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 2, 2023 CI
Novartis India Limited Recommends Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 2, 2023 CI
Novartis India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Novartis India Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Novartis India Board to Consider Interim Dividend for Fiscal 2023 MT
Novartis India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Novartis India Limited Announces Board Changes CI
Chart Novartis India Limited
More charts
Novartis India Limited is an India-based company that is engaged in the business of trading of pharmaceuticals. The Company's portfolio of medicines addresses various therapeutic needs, such as cardiovascular, eye care, immunology, metabolic, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India. In the bone and pain therapeutic area its brand is Voveran. In the transplantation immunology therapeutic area, the Company's brands include Simulect, Certican, Sandimmun, Neoral and Myfortic. In the neurosciences therapeutic area, its brands include Tegrital and Exelon.
More about the company
  1. Stock Market
  2. Equities
  3. NOVARTIND Stock
  4. News Novartis India Limited
  5. Novartis India : Net Profit Climbs in Fiscal Q1